The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019
Open accessAbstract
Background Tocilizumab, an IL-6 receptor antagonist, can be used to treat cytokine release syndrome (CRS), with observed improvements in a coronavirus disease 2019 (COVID-19) case series. Research Question The goal of this study was to determine if tocilizumab benefits patients hospitalized with COVID-19. Study Design and Methods This observational study of consecutive COVID-19 patients hospitalized between March 10, 2020, and March 31, 2020, and followed up through April 21, 2020, was conducted by chart review. Patients were treated with tocilizumab using an algorithm that targeted CRS. Survival and mechanical ventilation (MV) outcomes were reported for 14 days and stratified according to disease severity designated at admission (severe, ≥ 3 L supplemental oxygen to maintain oxygen saturation > 93%). For tocilizumab-treated patients, pre/post analyses of clinical response, biomarkers, and safety outcomes were assessed. Post hoc survival analyses were conducted for race/ethnicity. Results Among the 239 patients, median age was 64 years; 36% and 19% were black and Hispanic, respectively. Hospital census increased exponentially, yet MV census did not. Severe disease was associated with lower survival (78% vs 93%; P < .001), greater proportion requiring MV (44% vs 5%; P < .001), and longer median MV days (5.5 vs 1.0; P = .003). Tocilizumab-treated patients (n = 153 [64%]) comprised 90% of those with severe disease; 44% of patients with nonsevere disease received tocilizumab for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission levels of high-sensitivity C-reactive protein (120 vs 71 mg/L; P < .001) and received tocilizumab sooner (2 vs 3 days; P < .001), but their survival was similar to that of patients with nonsevere disease (83% vs 91%; P = .11). For tocilizumab-treated patients requiring MV, survival was 75% (95% CI, 64-89). Following tocilizumab treatment, few adverse events occurred, and oxygenation and inflammatory biomarkers (eg, high-sensitivity C-reactive protein, IL-6) improved; however, D-dimer and soluble IL-2 receptor (also termed CD25) levels increased significantly. Survival in black and Hispanic patients, after controlling for age, was significantly higher than in white patients (log-rank test, P = .002). Interpretation A treatment algorithm that included tocilizumab to target CRS may influence MV and survival outcomes. In tocilizumab-treated patients, oxygenation and inflammatory biomarkers improved, with higher than expected survival. Randomized trials must confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469
Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., Prill, M., Chai, S. J., Kirley, P. D., Alden, N. B., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6915e3 · Cited by 2,335
Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State
Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020) · JAMA · doi:10.1001/jama.2020.4326 · Cited by 2,259
Clinical Characteristics of Covid-19 in New York City
Goyal, P., Choi, J. J., Pinheiro, L. C., Schenck, E. J., Chen, R., Jabri, A., Satlin, M. J., Campion, T. R., Nahid, M., Ringel, J. B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2010419 · Cited by 2,234
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Research works printed but not linked: 21
- Sanders, 2020, pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA, 10.1001/jama.2020.6019 · DOI · Paper page
- Wang, 2020, C reactive protein level may predict the risk of COVID-19 aggravation, Open Forum Infect Dis, 7, ofaa153, 10.1093/ofid/ofaa153 · DOI · Paper page
- Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Intern Med, 10.1001/jamainternmed.2020.0994 · DOI · Paper page
- Yang, 2020, The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis, J Infect
- Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 · DOI · Paper page
- Michot, 2020, Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report, Ann Oncol, 10.1016/j.annonc.2020.03.300 · DOI · Paper page
- Zhang, 2020, The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality, Int J Antimicrob Agents, 55, 105954, 10.1016/j.ijantimicag.2020.105954 · DOI · Paper page
- Bersanelli, 2020, Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors, Immunotherapy, 10.2217/imt-2020-0067 · DOI · Paper page
- Xu, 2020, Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci U S A, 10.1073/pnas.2005615117 · DOI · Paper page
- Navarro, 2014, Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums, Semin Arthritis Rheum, 43, 458, 10.1016/j.semarthrit.2013.08.001 · DOI
- Chen, 2019, Management of cytokine release syndrome related to CAR-T cell therapy, Front Med, 13, 610, 10.1007/s11684-019-0714-8 · DOI
- Luo, 2020, Tocilizumab treatment in COVID-19: a single center experience, J Med Virol, 10.1002/jmv.25801 · DOI · Paper page
- Sciascia, 2020, Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19, Clin Exp Rheumatol
- Weissman, 2020, Locally informed simulation to predict hospital capacity needs during the COVID-19 pandemic, Ann Intern Med, 10.7326/L20-1062 · doi:10.7326/l20-1062
- Wells, 2020, Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA, Lancet Infect Dis, 10.1016/S1473-3099(20)30315-7 · DOI
- Weiss, 2020, Clinical course and mortality risk of severe COVID-19, Lancet, 395, 1014, 10.1016/S0140-6736(20)30633-4 · DOI · Paper page
- Yang, 2020, Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, 10.1016/S2213-2600(20)30079-5 · DOI · Paper page
- Bhatraju, 2020, COVID-19 in critically ill patients in the Seattle region—case series, N Engl J Med, 10.1056/NEJMoa2004500 · DOI · Paper page
- Bikdeli, 2020, COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up, J Am Coll Cardiol, 10.1016/j.jacc.2020.04.031 · DOI · Paper page
- Rubin, 1990, The soluble interleukin-2 receptor: biology, function, and clinical application, Ann Intern Med, 113, 619, 10.7326/0003-4819-113-8-619 · DOI · Paper page
- Feng, 2020, COVID-19 with different severity: a multi-center study of clinical features, Am J Respir Crit Care Med, 10.1164/rccm.202002-0445OC · DOI · Paper page
Cited by
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030340 · Cited by 1,291
The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings
Paterson, R. W., Brown, R. L., Benjamin, L., Nortley, R., Wiethoff, S., Bharucha, T., Jayaseelan, D. L., Kumar, G., Raftopoulos, R. E., Zambreanu, L., et al. (2020) · Brain · doi:10.1093/brain/awaa240 · Cited by 1,124
Salvarani, C., Dolci, G., Massari, M., Merlo, D. F., Cavuto, S., Savoldi, L., Bruzzi, P., Boni, F., Braglia, L., Turrà, C., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.6615 · Cited by 684
COVID-19 infection: an overview on cytokine storm and related interventions
Montazersaheb, S., Hosseiniyan Khatibi, S. M., Hejazi, M. S., Tarhriz, V., Farjami, A., Ghasemian Sorbeni, F., Farahzadi, R., & Ghasemnejad, T. (2022) · Virology Journal · doi:10.1186/s12985-022-01814-1 · Cited by 610
Metadata
- Authors
- Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., Mcmanus, D., Chen, S.-C., Gleeson, S. E., Britto, C. J., Azmy, V., Kaman, K., Gaston, D. C., Davis, M., Burrello, T., Harris, Z., Villanueva, M. S., Aoun-Barakat, L., Kang, I., Seropian, S., Chupp, G., Bucala, R., Kaminski, N., Lee, A. I., LoRusso, P. M., Topal, J. E., Dela Cruz, C., & Malinis, M.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 158
- Issue
- 4
- Pages
- 1397-1408
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W3089952857
- Cited by
- 204
- References
- 6
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019. https://app.cochat.ai/papers/10.1016/j.chest.2020.06.006
- The paper
- Price, C. C., Altice, F. L., Shyr, Y., Koff, A., Pischel, L., Goshua, G., Azar, M. M., Mcmanus, D., Chen, S.-C., Gleeson, S. E., Britto, C. J., Azmy, V., Kaman, K., Gaston, D. C., Davis, M., Burrello, T., Harris, Z., Villanueva, M. S., Aoun-Barakat, L., . . . Malinis, M. (2020). Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019. Chest. https://doi.org/10.1016/j.chest.2020.06.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.